Filing summary
Reporting-entity discrepancy: The supplied metadata identifies SS Innovations International, Inc., but the filing itself is a Form 10-Q for AVRA Medical Robotics, Inc. for the quarter ended March 31, 2021. It was signed November 3, 2022. Investors should verify the issuer, filing period, and filing history before relying on this summary.
Business context and reporting period
AVRA described itself as a development-stage medical robotics company pursuing an AI- and machine-learning-enabled robotic system, initially focused on aesthetic skin-resurfacing procedures. The statements are unaudited and cover the three months ended March 31, 2021, with comparison to the three months ended March 31, 2020. The company reported no revenue in either period and said results were not necessarily indicative of future periods.
Financial results and position
| Metric | Q1 2021 | Q1 2020 or prior balance-sheet date |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $300,078 | $306,671 |
| Net loss | $300,056 | $307,015 |
| Loss per share, basic and diluted | $0.01 | $0.01 |
| Cash and cash equivalents | $316,813 | $160,709 at Dec. 31, 2020 |
| Total assets | $466,635 | $317,870 at Dec. 31, 2020 |
| Total current liabilities | $1,226,140 | $1,186,919 at Dec. 31, 2020 |
| Stockholders’ deficit | $759,504 | $869,049 at Dec. 31, 2020 |
Operating expenses comprised $219,600 of compensation, $80,478 of general and administrative expense, and no research and development expense. The filing reports $22 of interest income and no income-tax provision. No operating margin is meaningful given the absence of revenue.
Net cash used in operations was $78,896, versus $50,354 in Q1 2020. There was no investing cash outflow in Q1 2021. Financing provided $235,000, reported as proceeds from a securities offering, resulting in a $156,104 increase in cash. The filing reports $195,000 of related-party notes payable and does not show a separate current portion of other debt on the balance sheet.
Changes and capital structure
Net loss narrowed by $6,959 year over year as operating expenses declined by $6,593. Compensation and general and administrative costs were slightly lower; research and development expense fell from $2,000 to zero. Cash increased from year-end primarily alongside equity financing. Issued and outstanding common shares rose from 25,721,971 at December 31, 2020 to 26,746,971 at March 31, 2021; the balance sheet also reports 345,480 shares as a common-stock liability.
Outlook, risks, contingencies, and unusual items
- Going concern: Management stated that the company had no established revenue sufficient to cover operating costs, depended on debt and equity financing, and faced substantial doubt about its ability to continue as a going concern. It had no committed funding sources and warned that financing could dilute existing shareholders or that operations might need to be curtailed.
- Development and regulatory risk: The company expected to require substantial funding for development, regulatory approval, manufacturing, and commercialization. Its anticipated regulatory pathway and commercialization timing were management expectations, not assured outcomes.
- Funding and related parties: The company reported recurring CEO/related-party borrowing and accrued compensation obligations. Its later-dated disclosures describe significant equity issuances and conversions of accrued amounts; these are not Q1 2021 results.
- Subsequent transaction disclosure: The filing describes an August 2022 non-binding letter of intent for a business combination with the SSI Parties, with proposed post-transaction ownership of 95% for SSI Parties’ shareholders and 5% for existing AVRA shareholders. Completion was subject to definitive agreements and due diligence, with no assurance of closing. The filing also describes interim financing and convertible notes associated with that proposal. These events occurred after the reported quarter.
- Controls: The filing says disclosure controls were not effective due to previously identified material weaknesses, but later language in the same section says controls were effective. It also refers to evaluation dates in 2020 and March 21, 2021, despite the March 31, 2021 reporting period. The disclosures are internally inconsistent.
- Other: The company disclosed COVID-19 uncertainty and no material off-balance-sheet arrangements. It reported no legal proceedings and no defaults upon senior securities.
Important facts to verify
- Whether this AVRA filing is the intended filing for SS Innovations International, Inc., and whether the 2021 Q1 period is correct.
- The filing’s late signature date and the applicable filing-status and amendment history.
- The financing and share-issuance figures: the cash-flow statement reports $235,000 of offering proceeds, while the stockholders’ deficit statement records $940,000 offering shares with a different reported amount. Reconcile the proceeds, share count, and accounting entries.
- The amount, maturity, and status of accrued compensation and related-party obligations, and the company’s near-term funding needs.
- The status and terms of the proposed SSI transaction and related interim financing, distinguishing those 2022 events from the Q1 2021 financial position.
- The actual status of internal-control weaknesses and the corrected evaluation dates, given conflicting statements in the filing.